01
May
Glenmark Pharmaceuticals Limited (Glenmark) has launched a fixed dose combination (FDC) of Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin (first-line medication for the treatment of type 2diabetes). Glenmark has launched the same under two brand names Remo MV and Remozen MV. In chronic diseases like Type 2 diabetes, patients are required to consume multiple anti-diabetic drugs for prolonged periods of time. This fixed drug combination is indicated for the management of Type 2 diabetes. The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000…